How an antibody may prevent allergic reactions

Researchers at Aarhus University have made a serendipitous discovery that could help an enormous amount of patients who suffer from allergies. Though they were searching for a way to improve existing allergy treatments, their data pointed to a new way to approach allergy treatment. Their results, published in Nature Communications, demonstrate how an antibody can be used to block the immune reaction that leads to allergy symptoms.

Normally, when patients with allergies are exposed to allergens, they produce large amounts of IgE molecules. These molecules travel through the blood and attach to immune system cells called effector cells. When this attachment occurs, histamine production is triggered, which leads to the allergic reaction that the patient experiences.

What scientists have found is that there is an antibody that can interfere with this binding of IgE to two types of effector cells (called CD23 and FceRI). Not only does the antibody block the IgE molecules from attaching to these effector cells, but it can also remove IgE molecules from effectors cells after they have become bound to them.

Certain features of this new antibody make it interesting to researchers and clinicians. For instance, it is much smaller than other antibodies that are currently used in allergy medications. It is also very stable and may be able to be inhaled or swallowed rather than injected into patients. In addition to being more convenient and less painful, this feature of the antibody may also make it less expensive than it otherwise could be.

While the research is still in the preclinical stages, the results are promising. If this antibody can prevent IgE-effector cell attachment, then the amount of IgE the body produces will not be indicative of the subsequent allergic reaction. More research will have to be conducted to determine if and how this antibody can be used to prevent allergic reactions in patients.

Author
Dr. Summit Shah

You Might Also Enjoy...

What will palforzia do for peanut allergy sufferers?

It is expected that the U.S. Food and Drug Administration (FDA) will approve a new drug that treats peanut allergies in children in January. The drug, developed by a California-based startup called Aimmune Therapeutics, is Palforzia...

Lessons From Asthma Peak Week

The 3rd week in September marked Asthma Peak Week for 2019. What is Asthma Peak Week? It is a week when certain conditions come together to create a perfect storm for asthma sufferers...

There’s a new vaccine for cat allergies

Roughly 1 in 10 people in the United States are allergic to cats. Despite exposure to cats resulting in symptoms including coughing, sneezing, wheezing, stuffy noses, and rashes in this part of our population,...

Sesame allergies: More common than we thought

Northwestern University researchers have found that sesame allergies are more common in the United States that experts previously thought. According to their analysis of data from 50,000 households and more than 80,000 people, sesame allergies affect...

What is Intermittent Asthma?

Many asthma sufferers do not realize that there are different types of asthma diagnoses that depend on the frequency of asthma symptoms. Whereas people who suffer from asthma symptoms regularly are often diagnosed with persistent asthma...